Original Source(s)
Related Content
FDA Expands Guselkumab Label in PsA
Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.
May 29, 2026
-
2 min
RA Prescribing Patterns Shift Over 15 Years
An aging Japanese cohort with rheumatoid arthritis saw increasing use of targeted synthetic therapies as glucocorticoid use declined.
May 29, 2026
-
5 min
AD Not Linked to Early CV Risk Markers
Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.
May 27, 2026
-
5 min